4-morpholin-4-yl-2-(naphthalen-1-ylmethylamino)-1H-pyrimidin-6-one | 1403662-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-morpholin-4-yl-2-(naphthalen-1-ylmethylamino)-1H-pyrimidin-6-one
• CAS: 1403662-91-8
• 化学式: C₁₉H₂₀N₄O₂
• 分子量: 336.393
• InChiKey: VNMOCXVCBXMWMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-溴甲基萘 在 potassium carbonate 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 、 乙腈 为溶剂， 反应 0.99h， 生成 4-morpholin-4-yl-2-(naphthalen-1-ylmethylamino)-1H-pyrimidin-6-one
  参考文献：
  名称：

  Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance

  摘要：

  Structure-based evolution of the original fragment leads resulted in the identification of 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, (S)-21, a potent, selective phosphoinositide 3-kinases (PI3K) p110 beta isoform inhibitor with favourable in vivo antiplatelet effect. Despite its antiplatelet action, (S)-21 did not significantly increase bleeding time in dogs. Additionally, due to its enhanced selectivity over p110 alpha, (S)-21 did not induce any insulin resistance in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.102

文献信息

• Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation
  作者：Fabrizio Giordanetto、Andreas Wållberg、Johan Cassel、Saswati Ghosal、Michael Kossenjans、Zhong-Qing Yuan、Xiaoping Wang、Lifeng Liang

  DOI：10.1016/j.bmcl.2012.08.101

  日期：2012.11

  The discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing inhibitors of Phosphoinositide 3-kinases (PI3K) p110 beta isoform is reported. Structure-based optimisation of the original fragment hit resulted in lead compounds with improvements in ligand efficiency, lipophilicity efficiency, p110 beta potency and selectivity over p110 alpha. (C) 2012 Elsevier Ltd. All rights reserved.
• Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance
  作者：Fabrizio Giordanetto、Andreas Wållberg、Saswati Ghosal、Tommy Iliefski、Johan Cassel、Zhong-Qing Yuan、Henrik von Wachenfeldt、Søren M. Andersen、Tord Inghardt、Anders Tunek、Sven Nylander

  DOI：10.1016/j.bmcl.2012.08.102

  日期：2012.11

  Structure-based evolution of the original fragment leads resulted in the identification of 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, (S)-21, a potent, selective phosphoinositide 3-kinases (PI3K) p110 beta isoform inhibitor with favourable in vivo antiplatelet effect. Despite its antiplatelet action, (S)-21 did not significantly increase bleeding time in dogs. Additionally, due to its enhanced selectivity over p110 alpha, (S)-21 did not induce any insulin resistance in rats. (C) 2012 Elsevier Ltd. All rights reserved.